These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28418683)

  • 1. Physical Characterization of Tobramycin Inhalation Powder: II. State Diagram of an Amorphous Engineered Particle Formulation.
    Miller DP; Tan T; Nakamura J; Malcolmson RJ; Tarara TE; Weers JG
    Mol Pharm; 2017 Jun; 14(6):1950-1960. PubMed ID: 28418683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physical Characterization of Tobramycin Inhalation Powder: I. Rational Design of a Stable Engineered-Particle Formulation for Delivery to the Lungs.
    Miller DP; Tan T; Tarara TE; Nakamura J; Malcolmson RJ; Weers JG
    Mol Pharm; 2015 Aug; 12(8):2582-93. PubMed ID: 26052676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X; Vogt FG; Hayes D; Mansour HM
    Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation.
    Wu X; Hayes D; Zwischenberger JB; Kuhn RJ; Mansour HM
    Drug Des Devel Ther; 2013; 7():59-72. PubMed ID: 23403805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid assessment of the structural relaxation behavior of amorphous pharmaceutical solids: effect of residual water on molecular mobility.
    Miller DP; Lechuga-Ballesteros D
    Pharm Res; 2006 Oct; 23(10):2291-305. PubMed ID: 16955371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spray-dried carrier-free dry powder tobramycin formulations with improved dispersion properties.
    Pilcer G; Vanderbist F; Amighi K
    J Pharm Sci; 2009 Apr; 98(4):1463-75. PubMed ID: 18752304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical characterization and water vapor sorption of organic solution advanced spray-dried inhalable trehalose microparticles and nanoparticles for targeted dry powder pulmonary inhalation delivery.
    Li X; Mansour HM
    AAPS PharmSciTech; 2011 Dec; 12(4):1420-30. PubMed ID: 22038473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of a single-use, capsule-free multi-breath tobramycin dry powder inhaler for the treatment of cystic fibrosis.
    Zhu B; Padroni M; Colombo G; Phillips G; Crapper J; Young PM; Traini D
    Int J Pharm; 2016 Dec; 514(2):392-398. PubMed ID: 27063852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
    Karimi K; Katona G; Csóka I; Ambrus R
    J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate.
    Simon A; Amaro MI; Cabral LM; Healy AM; de Sousa VP
    Int J Pharm; 2016 Mar; 501(1-2):124-38. PubMed ID: 26836711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
    Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
    J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review.
    Vandevanter DR; Geller DE
    Med Devices (Auckl); 2011; 4():179-88. PubMed ID: 22915944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers.
    Li X; Vogt FG; Hayes D; Mansour HM
    J Pharm Sci; 2014 Sep; 103(9):2937-2949. PubMed ID: 24740732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis.
    Pilcer G; De Bueger V; Traina K; Traore H; Sebti T; Vanderbist F; Amighi K
    Int J Pharm; 2013 Jul; 451(1-2):112-20. PubMed ID: 23643509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of small amorphous amounts in hydrophilic and hydrophobic APIs on storage stability of dry powder inhalation products.
    Müller T; Krehl R; Schiewe J; Weiler C; Steckel H
    Eur J Pharm Biopharm; 2015 May; 92():130-8. PubMed ID: 25769680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
    Somayaji R; Parkins MD
    Ther Deliv; 2015 Feb; 6(2):121-37. PubMed ID: 25690082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer™ family.
    Hoppentocht M; Akkerman OW; Hagedoorn P; Frijlink HW; de Boer AH
    Eur J Pharm Biopharm; 2015 Feb; 90():8-15. PubMed ID: 25615881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation.
    Pilcer G; Sebti T; Amighi K
    Pharm Res; 2006 May; 23(5):931-40. PubMed ID: 16715383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
    Pierart F
    Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
    Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
    Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.